Inmune Bio Secures Long-Term Supply for CORDStrom™ Platform, Strengthening Pipeline Amidst Going Concern Concerns

summarizeSummary

Inmune Bio entered into an amended and restated Material Transfer and License Agreement with Anthony Nolan, securing a long-term supply of umbilical cord tissue for its CORDStrom™ platform, with the parent company now jointly liable for future royalties.

check_boxKey Events

• Expanded Strategic Collaboration

  Inmune Bio Inc. entered into an amended and restated Material Transfer and License Agreement with Anthony Nolan, a UK charity, expanding their collaboration for the CORDStrom™ platform.

• Secures Long-Term Material Supply

  The agreement secures the long-term provision of high-quality umbilical cord tissue, essential for powering Inmune Bio's CORDStrom™ Mesenchymal Stromal Cell (MSC) technology.

• Parent Company Assumes Liability

  Inmune Bio Inc. (the parent company) has agreed to be jointly and severally liable with its subsidiary for payment obligations, including a 2% royalty on net sales of each Product, capped at £5,000,000 annually.

• Focus on Key Therapeutic Areas

  The collaboration is initially focused on developing treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB), oncology (solid tumors), osteoarthritis, and Systemic Lupus Erythematosus (SLE).

auto_awesomeAnalysis

This filing details a critical strategic agreement for Inmune Bio, securing the long-term supply of high-quality umbilical cord tissue for its CORDStrom™ platform. This is a significant positive development, especially in light of the company's recent 10-K filing which expressed substantial doubt about its ability to continue as a going concern following a lead drug failure. By solidifying the supply chain for a core product platform targeting RDEB, oncology, and inflammatory diseases, Inmune Bio is strengthening its future commercialization potential and addressing a key operational challenge. The parent company's joint liability for royalties underscores the strategic importance of this collaboration. While not an immediate financing event, it lays essential groundwork for future revenue generation, which is vital for the company's long-term viability.